Return to the catalog
AOD-9604
NewOut of stock5mg vial

AOD-9604

Modified fragment of growth hormone studied for fat breakdown without affecting blood sugar or growth.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

Pricing coming soon

Contact us for a quote on this batch.

Bacteriostatic water included

99%+ Purity
Extensively Researched

About this peptide

AOD-9604 is a short piece of human growth hormone — the tail end (amino acids 177–191) with one extra amino acid added for stability. Researchers isolated this fragment because it appears to carry growth hormone's fat-burning signal without its effects on blood sugar or tissue growth. It was taken through human clinical trials for weight management and is studied today in fat metabolism and cartilage research.

Why researchers reach for AOD-9604

Fat-metabolism research

Studied for stimulating fat breakdown (lipolysis) and blocking new fat formation in fat-cell models.

No blood-sugar effect

Unlike full growth hormone, trials reported no impact on insulin sensitivity or glucose levels.

Human safety data

One of the few peptide fragments with published human safety studies from its clinical-trial programme.

Key features

  • 99%+ purity verified by HPLC
  • Tyr-modified hGH fragment 177-191
  • Lyophilised powder for stability
  • 5 mg research vial
  • Bacteriostatic water included
  • For laboratory research use only

How it works

Growth-hormone tail fragment

Mimics the C-terminal region of hGH that is linked to fat metabolism, without binding the growth-hormone receptor in a way that drives growth.

Lipolysis stimulation

Promotes release of stored fat from adipocytes, partly through beta-3 adrenergic signalling.

Lipogenesis inhibition

Reduces the conversion of dietary energy into new stored fat in animal models.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Reported research range250–500 mcgPer administration in injectable research protocols; human trials used 1 mg/day orally.
Frequency1× dailyClinical programmes used daily dosing over 12 weeks.
Typical reconstitution2 mL bacteriostatic waterYields 2.5 mg/mL (2500 mcg/mL).
Anti-gelling reconstitution0.6% sterile acetic acidUsed in place of, or before, bacteriostatic water to keep the peptide fluid and stop gelling. Add slowly down the vial wall and swirl gently — do not shake.

Tracking this compound? Registered researchers can log active AOD-9604 protocols in their private Research Log.

Timing in research protocols

Once daily; morning fasted timing is protocol convention rather than trial evidence.

  • Human clinical trials used once-daily oral dosing for 12 weeks.
  • Fasted-morning dosing in research protocols follows growth-hormone fat-metabolism physiology, not a timing trial.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Scientific name
Tyr-hGH(177-191), anti-obesity drug 9604
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
CAS number
221231-10-3
Molecular weight
~1815 Da
Purity
99%+ (HPLC)
Form
Lyophilised white powder
Vial size
5 mg
Reconstitution
2 ml bacteriostatic water
Anti-gelling solvent
0.6% sterile acetic acid if gelling occurs
Storage (unopened)
-20 degrees C, protected from light
Storage (reconstituted)
2-8 degrees C, use within 30 days

Published research

Peer-reviewed literature on AOD-9604. Links open in a new tab.

Research use notice

AOD-9604 is supplied strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical application.

#aod-9604#hgh-fragment#lipolysis#fat-loss#metabolic

Cart (0)

Your cart is empty